A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer

Haidy Nasief, Cheng Zheng, Diane Schott, William Hall, Susan Tsai, Beth Erickson and X. Allen Li

Changes of radiomic features over time in longitudinal images, delta radiomics, can potentially be used as a biomarker to predict treatment response. This study aims to develop a delta-radiomic process based on machine learning by (1) acquiring and registering longitudinal images, (2) segmenting and populating regions of interest (ROIs), (3) extracting radiomic features and calculating their changes (delta-radiomic features, DRFs), (4) reducing feature space and determining candidate DRFs showing treatment-induced changes, and (5) creating outcome prediction models using machine learning. This process was demonstrated by retrospectively analyzing daily non-contrast CTs acquired during routine CT-guided-chemoradiation therapy for 90 pancreatic cancer patients. A total of 2520 CT sets (28-daily-fractions-per-patient) along with their pathological response were analyzed. Over 1300 radiomic features were extracted from the segmented ROIs. Highly correlated DRFs were ruled out using Spearman correlations. Correlation between the selected DRFs and pathological response was established using linear-regression-models. T test and linear-mixed-effects-models were used to determine which DRFs changed significantly compared with first fraction. A Bayesian-regularization-neural-network was used to build a response prediction model. The model was trained using 50 patients and leave-one-out-cross-validation. Performance was judged using the area-under-ROC-curve. External independent validation was done using data from the remaining 40 patients. The results show that 13 DRFs passed the tests and demonstrated significant changes following 2–4 weeks of treatment. The best performing combination differentiating good versus bad responders (CV-AUC = 0.94) was obtained using normalized-entropy-to-standard-deviation-difference-(NESTD), kurtosis, and coarseness. With further studies using larger data sets, delta radiomics may develop into a biomarker for early prediction of treatment response.
process based on machine learning and tested the process by analyzing the longitudinal CTs acquired during CRT for pancreatic cancer.

RESULTS

The proposed delta-radiomics process and the machine-learning algorithms were successfully used to perform the delta-radiomics analysis on the selected patient data. Major findings are described below.

Selection of delta-radiomics features

It was found that based on the Spearman correlation coefficients obtained, a total of 73 DRFs extracted from the segmented pancreas head of each daily CT set had $r_s < 0.9$, i.e., not containing redundant information, thus, justifying the use of these features for the delta-radiomics analysis. This DRF set was examined across all patients to ensure its reproducibility. Figure 1 shows a sample of the numerical correlation coefficients, the histograms, and the scatter plot (left), Spearman ranking (middle) showing colored dots whose size and color correspond to the correlation value and white blocks representing insignificant coefficients, and an example of a Spearman correlation heatmap for some of the DRFs (right).

Effects of respiration motion and CT acquisition

To select the DRFs that are not substantially affected by respiratory motion, all extracted features were compared between the low and high motion groups. It was found that, among the extracted DRFs, 35% were affected by the motions with COV > 5%, of which 45% had a COV < 10%. The effect of motion was more apparent for the higher order features extracted on the daily CTs acquired between weeks 2 and 4 of the treatment. The mean, mean absolute deviation, autocorrelation, text strength, inverse difference normalized, information measure, inverse variance, sum average, gray level nonuniformity, and the newly developed NESTD are examples of the features with less motion dependence (COV <5%) and nonsignificant p-values from both the t-test and the MSLR test. A comparison of two DRFs, one with large motion effect (cluster prominence, top left) and another with small motion effect (texture strength, top right) in different weeks between the low and high motion groups and the difference in the COV for selected DRFs (bottom) between the two groups are shown in Fig. 2. The weekly DRF value (top left and right panels in Fig. 2) combines the DRF values of all five fractions in the week.

For the effect of the different acquisition parameters (scanners), the t-test and regression analysis showed that there was no significant difference ($p > 0.05$) in the selected DRFs between the two different acquisition protocols, indicating the DRFs can be used for all the selected patient data obtained from the two CT scanners.

Correlation with treatment outcomes

It was found from the linear regression analysis that 27 out of the 47 DRFs that were not affected by both respiratory motion and image acquisition exhibited a trend to correlate with the pathological response. These DRFs include autocorrelation, cluster shade, cluster tendency, coarseness, complexity, contrast, difference entropy, dissimilarity, energy, entropy, mean, median, standard deviation, global uniformity, gray level nonuniformity, high gray level run emphasis, homogeneity, information measure, inverse difference normalized (IDN), inverse variance, kurtosis, skewness, NESTD, short-run emphasis, max probability, mean absolute deviation, and run percentage. The values of these DRFs were different between the good- and bad-response groups, indicating their associations with the responses.

Figure 3 presents comparisons of sample DRFs between the good and bad-response groups in boxplots, showing (a) the average DRFs for all fractions for the maximum to mean ratio (MaxMean, left) feature with no significant difference (t-test $p$-value > 0.05) between the two response groups, where the DRF value for each patient was the average of all fractions, and the average DRFs for all fractions of the contrast feature (right) exhibiting significant changes ($p < 0.05$) between the good- and bad-response groups, the presented boxplots show the median and interquartile range for each response group and the diamond data point in the middle represents the mean of the group, and (b) examples of distribution of good- and bad-response group including all patients and all fractions within each response group for coarseness, kurtosis, NESTD, and contrast during the entire course of treatment.

Figure 4 compares the boxplots and the $p$-values of daily DRFs of contrast feature for all patients in a response group between the two response groups, showing (a) all daily DRFs for both groups plotted together and (b) DRFs for the two response groups plotted for each fraction. In fractions 14–18, the differences in the daily DRFs between the two response groups are significant in four consecutive fractions ($p < 0.05$).

Based on the analysis with t-test and linear mixed-effects model, it was found that 13 of the 27 selected DRFs passed both tests with $p$-value < 0.05, indicating their significant correlations with the pathological response. These candidate DRFs included complexity, cluster tendency, coarseness, information measure, contrast, entropy, inverse variance, gray level nonuniformity, mean, IDN, kurtosis, skewness, and NESTD. Shape features did not show significant correlation to the treatment response.
Prediction model building using machine-learning algorithms

Different weight planes for different DRFs were obtained from the SOM confirming that the candidate DRFs were not highly correlated. The SOM showed some degree of overlap in the candidate DRFs values between the two response groups. To determine whether the candidate DRFs, identified by the analysis of using the mixed-effect model and t test and confirmed by the self-organizing map (SOM), can be used to distinguish the good or bad response, they were used to build a response prediction model using a Bayesian regularization backpropagation neural network. Based on the network using the DRFs confirmed by the self-organizing maps, seven individual candidate DRFs (kurtosis, skewness, coarseness, NESTD, IDN, mean, and contrast) were identified to have the strongest correlation with the response, thus, could be used to build a response prediction model.

The prediction model was improved by combining the DRFs. The best performing two-feature combination with cross validated area under the ROC curve (CV-AUC) of 0.92 was found to be for the kurtosis–coarseness combination. The performance increased to 94% using the kurtosis–coarseness–NESTD combination with an accuracy of 0.94. It is clear that these DRFs and their appropriate combinations can accurately predict the treatment response.

**DISCUSSION**

As demonstrated in this work, delta radiomics is a quantitative method that can assess the treatment-induced net change of radiomic features over time and may be used for early prediction of treatment response during the treatment. A rigorous delta-radiomics analysis process to select appropriate DRFs to predict response was developed and demonstrated based on the 28 daily CT sets collected acquired during routine CT-guided CRT and pathological treatment response data for 90 pancreatic cancer patients. The process has identified appropriate delta-radiomic features that can predict treatment pathological response during the CRT delivery.

One limitation of delta radiomics is contour variations between the image sets that can affect the reproducibility of the results.17 Our newly developed NESTD map provided a useful tool to detect structure boundaries and to adjust the contours as needed for a more robust and reproducible feature extraction process. Another limitation, common for any radiomics work, is the restriction for using the data with certain technical and patient variations, e.g., from different scanners or different institutions, limiting the size of the data that can be used to train deep networks.17 For delta radiomics, however, DRFs are the relative values that may not strongly depend on certain imaging variations. For example, this study shows that variations in imaging parameters from two different scanners did not affect the DRF analysis. On the other hand, the data for patients with large amounts of motion or stent...
artifact that distort image quality needed to be excluded as they can introduce errors in DRFs. An exception is that certain features, which can have a low coefficient of variance, thus, can be less affected by the amount of motion, can still be identified as potential candidate DRFs.

The use of machine-learning algorithms appears to be an effective approach to build a response prediction model based on DRFs. Some potential problems can arise when implementing a neural network and limit its performance, such as local minima, overfitting, or classifying external independent data set as an outlier. In this study, the use of Bayesian regularization and Mahalanobis distance can account for these potential problems. The results reported here show promising initial results and demonstrate the need to further test this approach by using more patient data or data of other treatment or tumor sites. Larger data sets would improve the robustness of the neural network training using a variety of features including higher order features. More rigorous outcome data (e.g., local tumor control, survival) would help strengthen the correlation analysis. With further studies based on large and diversified patient data sets, the proposed

**Fig. 3** DRFs $t$ test and distributions. Boxplots and corresponding $t$ test $p$-value for (a) average DRFs of all fractions for maximum to mean ratio (MaxMean) feature indicating no significant difference between the two response groups and for the contrast feature showing significant differences. The presented boxplots show the median and interquartile range for each response group, and the diamond data point in the middle represents the mean of the group, (b) distribution of good- and bad-response group including all patients and all fractions within each response group for Coarseness, Kurtosis, NESTD, and contrast.
delta-radiomics process may be developed as an invaluable tool to identify imaging biomarkers for individualized treatment, e.g., guide adaptive radiation therapy.

**METHODS**

A general delta-radiomic process

We propose a delta-radiomic process based on machine learning. The process starts with acquiring a set of longitudinal images at different time points during treatment, followed with segmenting regions of interest (ROIs) on the image at the first time point. The longitudinal images are registered with each other either rigidly or deformably. The segmented ROIs are then populated to the images at the subsequent time points. The quality of the ROI contours is checked, either manually or automatically, to ensure their consistency over time. Radiomic features are extracted from the segmented ROIs from each time point and the changes in these radiomic features (i.e., DRFs) from those at the first time point are calculated. Due to the large number of radiomic features that can be extracted from the images, a Spearman correlation is used to rule out redundant DRFs. The selected DRFs are then tested to determine their significance as a function of treatment response using linear regression models, t test and mixed-effect models. Significant DRFs are further tested and modeled using machine-learning algorithms to create a model that can be used to predict outcome of a new patient. Figure 6 shows this general process for the delta-radiomics analysis. This process and the details of the machine-learning algorithms are further explained using the patient imaging and outcome data described below.

**Patient data**

The proposed delta-radiomics process is demonstrated and tested by retrospectively analyzing the imaging and outcome data collected from 90 pancreatic cancer patients treated in our clinic in compliance with the relevant HIPPA guidelines and regulations. Written consent was waived for retrospective studies under the Medical College of Wisconsin IRB approval. All patients had resectable or borderline resectable pancreatic head tumor, and were treated with pre-operative chemotherapy with Folfinox or Folfox.
and concurrent CRT with gemzar or gemcitabine followed by surgery during the period between 2012 and 2017. All RT were delivered with daily guidance of non-contrast CTs acquired using two in-room CT scanners (installed in two RT rooms) immediately prior to each delivery. These daily CTs were analyzed. The patients had a median age of 67 years at the start of treatment, with 54% males and 46% females.

All patients underwent pancreatectomy after CRT with gross and microscopic pathology reported. The surgical specimen was fixed in formalin overnight, and then the pancreas was serially sectioned. The area of tumor and surrounding fibrosis in the pancreas were submitted for microscopic examination. Hematoxylin and eosin sections were prepared, and treatment effect was evaluated. A modified Ryan Scheme for tumor regression score recommended by the College of American Pathologists was used to evaluate treatment effect as follows: Grade 0 (G0): no viable cancer cells (complete response), Grade 1 (G1): single cells or small groups of residual cancer (near complete response), Grade 2 (G2): residual cancer with evident tumor regression, but more than single cells or rare small groups of cancer cells (partial response), and Grade 3 (G3): extensive residual cancer without evident regression (poor or no response).23 Among the 90 patients, there were 50 patients with good pathological response (G1 and G2), and 40 with bad pathological response (G3). These good- and bad-pathological response data were used to create the good and bad groups used in our analysis.

**Table 1.** The best performing two- and three-feature combinations as judged by the AUC and the confidence interval

| Two-features combination | AUC   | Confidence interval |
|--------------------------|-------|---------------------|
| Kurtosis, coarseness     | 0.92  | [0.90, 0.95]        |
| NESTD, coarseness        | 0.90  | [0.89, 0.97]        |
| Kurtosis, NESTD          | 0.89  | [0.84, 0.91]        |
| Kurtosis, skewness       | 0.88  | [0.84, 0.92]        |
| Two features combination | AUC   | Confidence interval |
| Kurtosis, coarseness, NESTD | 0.94 | [0.91, 0.95] |
| Skewness, contrast, IDF  | 0.93  | [0.91, 0.95]        |
| Kurtosis, NESTD, skewness| 0.82  | [0.90, 0.95]        |
| Kurtosis, skewness, mean | 0.88  | [0.85, 0.91]        |

CT acquisition parameters

To include more patient data while ensuring a robust model and exclude DRFs that are affected by acquisition parameter variations, the daily CT data were obtained from patients scanned using two Siemens CT scanners (in-room CTs) with slightly different acquisition parameters. The first group included daily CT data acquired from 50 patients using a CT scanner (Definition AS, Siemens), with a standard abdominal protocol consisting of the following parameters: 120 kVp tube voltage, 252 mA tube current, 0.5 s, 1.2-mm focal spot, and standard filtered back-projection (FBP) algorithm with B30f kernels. The second group included daily CT data from 40 patients scanned using a different CT scanner (Emotion, Siemens) with another standard abdominal protocol employing the following parameters: 130 kVp tube voltage, 226 mA tube current, 0.6 s, 0.95-mm focal spot, and standard FBP with B31s kernels. All analyzed CTs were reconstructed in a $512 \times 512 \times Z$ (slices) voxels with resolution $0.98 \text{mm} \times 0.98 \text{mm} \times 3 \text{mm}$. To assess the effect of the acquisition parameters on radiomic feature selection, patients with the same pathological response were divided into two groups based on the two acquisitions, and a multivariate regression analysis was used to determine the effect of acquisition protocols on the DRFs.

For each patient, daily CT sets were collected from the 28 treatment fractions during the delivery of CRT of 50.4 Gy in 28 daily fractions, resulting in a total of 2520 daily CT sets for analysis. For patients with respiratory motion >8 mm ($n = 30$), the daily CTs were acquired with respiratory gating, reducing the motion to below 3 mm (the residual motion in the gating window) during the CT acquisition. For each patient, daily CTs were registered rigidly with each other with manual adjustment, if necessary, to achieve the best local matching between the CT sets. For each case, the contour of pancreatic head was delineated on the contrast-enhanced simulation CT and MRI and was populated to the CT of the first day (the first RT fraction), then to other daily CTs based on rigid image registration. The obtained contours were edited by experienced researchers using MIM software and verified independently by other experienced researchers to ensure consistency. In addition, these contours were checked using a new method proposed in this work (see below).

To minimize the effect of interfraction variation, daily CTs were registered locally based on the obtained contours. To estimate the effect of intrafraction (mostly respiratory) motions on DRFs, patients with the same pathological response were divided into two groups: low ($<3 \text{mm}$) and high ($3-8 \text{mm}$) motions, to examine the effect of motion on DRFs and to ensure that the DRFs selected for building the prediction model are not affected by the motions.

**Fig. 5** 3D scatter plots for the best performing feature combination. The weekly DRFs for weeks 2–4 for 50 good responders (150 data points) and the 40 bad responders (120 data points) for the best performing features combinations (kurtosis–NESTD–coarseness) is displayed and concurrence CRT with gemzar or gemcitabine followed by surgery during the period between 2012 and 2017. All RT were delivered with daily guidance of non-contrast CTs acquired using two in-room CT scanners (installed in two RT rooms) immediately prior to each delivery. These daily CTs were analyzed. The patients had a median age of 67 years at the start of treatment, with 54% males and 46% females.

All patients underwent pancreatectomy after CRT with gross and microscopic pathology reported. The surgical specimen was fixed in formalin overnight, and then the pancreas was serially sectioned. The area of tumor and surrounding fibrosis in the pancreas were submitted for microscopic examination. Hematoxylin and eosin sections were prepared, and treatment effect was evaluated. A modified Ryan Scheme for tumor regression score recommended by the College of American Pathologists was used to evaluate treatment effect as follows: Grade 0 (G0): no viable cancer cells (complete response), Grade 1 (G1): single cells or small groups of residual cancer (near complete response), Grade 2 (G2): residual cancer with evident tumor regression, but more than single cells or rare small groups of cancer cells (partial response), and Grade 3 (G3): extensive residual cancer without evident regression (poor or no response).23 Among the 90 patients, there were 50 patients with good pathological response (G1 and G2), and 40 with bad pathological response (G3). These good- and bad-pathological response data were used to create the good and bad groups used in our analysis.

**Table 1.** The best performing two- and three-feature combinations as judged by the AUC and the confidence interval

| Two-features combination | AUC   | Confidence interval |
|--------------------------|-------|---------------------|
| Kurtosis, coarseness     | 0.92  | [0.90, 0.95]        |
| NESTD, coarseness        | 0.90  | [0.89, 0.97]        |
| Kurtosis, NESTD          | 0.89  | [0.84, 0.91]        |
| Kurtosis, skewness       | 0.88  | [0.84, 0.92]        |
| Two features combination | AUC   | Confidence interval |
| Kurtosis, coarseness, NESTD | 0.94 | [0.91, 0.95] |
| Skewness, contrast, IDF  | 0.93  | [0.91, 0.95]        |
| Kurtosis, NESTD, skewness| 0.82  | [0.90, 0.95]        |
| Kurtosis, skewness, mean | 0.88  | [0.85, 0.91]        |

**Contour validation**

Accurate and consistent segmentation between daily CTs is essential to improve the accuracy and reproducibility of the extracted DRFs. Since manual segmentation can vary significantly among even well-trained observers,24 it is desirable to develop a new method to reduce the segmentation variation. To do so, we introduced a new feature (normalized entropy to standard deviation difference, NESTD) that combines the GLCM “entropy” feature and the histogram “Standard Deviation (STD)” feature. This new feature can be used to improve the detection of organ boundaries and to provide a way to standardize contour validation.

To obtain NESTD, a square ROI containing the pancreas and the surrounding tissue was defined for each CT slice. Normalized color encoded entropy and standard deviation maps were generated, using a script implementing MATLAB® built-in functions (“entropyfilt” and “stdfilt”). For each map, the output pixel contains the feature value of a 3-by-3 neighborhood around the corresponding pixel in the input image. For pixels on the borders of the input image, a symmetric padding was used (i.e., the values of the padding pixels were a mirror reflection of the border pixels). The NESTD map was generated by taking the difference between the normalized entropy and standard deviation maps and was applied to detect the boundaries of different organs and to adjust the contours if necessary.24 Figure 7 shows an example of the entropy, standard deviation, and the resultant NESTD map for one CT slice. The same process was repeated for all the slices covering the pancreatic head. To evaluate the effectiveness of using the NESTD map for contour validation, the resultant map was overlaid on the original CT where the pancreas head was delineated. If the contour included tissue other than the pancreatic head, the contour would be adjusted. To obtain a feature value, the average of the values of the NESTD over the entire 3D tumor was used.

In this study, the contours generated manually were validated utilizing the NESTD map, and were adjusted if necessary. For example, the vessels
A general delta-radiomics process. Including extracting delta-radiomics features and building machine-learning models for treatment outcome prediction.

1) Acquire Longitudinal images from different timepoints
2) Segment ROI on the first available time point
3) Register Images and Transfer ROI
4) Contour QA checks to confirm and adjust ROI
5) Extract Radiomic Features from segmented ROIs
6) Calculate Delta Radiomic features (DRFs)
7) Divide the extracted DRFs into classes based on outcomes
8) Determine DRFs showing significant difference from first fraction as function of
9) Feed significant DRFs into a shallow neural network with self organized map to
10) Examine and verify the selected DRFs and feed into a feedforward backpropagation neural network
11) generate bootstraps sample from the longitudinal data for the feedforward backpropagation neural network
12) Train the neural network with Bayesian regularization scheme to avoid overfitting
13) Use a leave one out validation method and AUC under ROC curve to judge the network performance
14) Use external independent validation set and classify utilizing the Mahalanobis distance to the centroid of the training class

Pathological response
Survival rate
ETC.

Machine Learning process for delta-Radiomics

Train
Validate
Test

Predict Outcomes

Fig. 6
that were not easily visualized on the CT and were included in the manual contour can be excluded by utilizing the new feature map.

Delta-radiomics features
CT texture analysis was performed to extract over 1300 radiomic features from the segmented ROIs, using an available software package, IBEX. Features extracted included intensity-based histogram, gray level run-length matrix (GLRLM)25,26, gray level co-occurrence matrix (GLCM)27-30, neighbor gray tone difference matrix (NGTDM),26,31 intensity histogram Gaussian fit, shape-based features,27-32 and our newly proposed NESTD feature.24

Since relatively high numbers of extracted radiomic features compared with the sample size can reduce the statistical power and increase the probability of data overfitting, a Spearman rank-order correlation coefficient was used to rule out low-rank redundant features (r ≥ 0.9). To reduce directional dependence, GLCMs for a distance d = 1 and a particular direction were summed over the set of axial slices. These direction-specific matrices were then summed and averaged to create the final GLCM for the 3D ROI.27,28 Similarly, the GLRNLs were calculated in the 0 and 90 directions, and then summed and averaged to create a global 3D run-length matrix.32,34

The DRF of a radiomic feature at the nth fraction was calculated as the relative change of the feature value from its value at the first fraction, such that:

\[
DRFn = \frac{\text{Feature value}_{\text{Fac } n} - \text{Feature value}_{\text{Fac } 1}}{\text{Feature value}_{\text{Fac } 1}}, \quad n = 2:28
\]  

All DRFs were categorized based on the coefficient of variance (COV). The p-values of the t test and the modified signed-likelihood ratio test (MSLR) for equality of COV were calculated to assess the robustness of DRFs using R® software.24

Spearman correlations, coefficient of variance (COV), and the modified signed-likelihood ratio test (MSLR) for equality of COV, and the t test, regression models, linear mixed-effects models that will be discussed in the next sections were built using R® built-in ggpubr, corrplot, lme4, dataarim, cvequality packages, and functions.

Machine-learning Algorithms
For the analysis of correlation between DRFs and pathological response, DRFs that were not prone to motion variation and/or acquisition parameters (due to the choice of acquisition parameters) were used in a machine-learning process. This process started with dividing the data set into two groups, good-(50 cases with 28 fractions each) and bad-(40 cases with 28 fractions) 28 response groups, based on their pathological response to CRT. To determine potential DRFs that could correlate to treatment response, DRFs were evaluated to determine when they started to change during the treatment as compared with their values at the first fraction and if these changes were different between the patients with good and bad responses. A metric trend was established using a linear regression model to find the best fit for each feature versus response and determine those with potential trends. A t test was performed to determine which DRFs changed significantly between the two response groups for the entire course of treatment, between two time points (e.g., daily, weekly) to pinpoint the time at which significantly different changes between the two response groups occurred. Features were also evaluated to determine if they changed during the treatment by fitting linear mixed-effects models using R® software for the DRFs as a function of response with two random effects as follows:

\[
\text{[model] = lme(DRF ~ Response + (1|Patient) + (1|Fraction)\ ]}
\]  

The first random effect assumes a different intercept for each patient to account for patient-dependent variation. The second random effect accounts for the fractional-dependent variation from the longitudinal study. The p-value of the log likelihood ratio for each model was calculated. The features that showed a trend and followed both the linear mixed-effect model and the t test (p < 0.05) were selected to be used to build a model to predict treatment response as early as possible during treatment.

To confirm that the DRFs selected by the t test, regression model and the linear mixed-effect model are appropriate and to ensure these features are not highly correlated to each other, a self-organizing neural network was built using the Matlab built-in neural clustering app to cluster the data based on the similarity while considering clustering in multiple dimensions. The training was performed using a batch algorithm, the slope of the DRFs over time for each data set was presented to the network before any weight was updated. The algorithm then determined a winning neuron for each input vector. Each of the weight vectors was updated such that it moves to the average position of all input vectors for which it or a neighbor neuron was a winner. Using self-organizing map, the weight plane of each feature used in the training process can be visualized. This can provide us with information regarding the potential of using a feature to discriminate between the two response groups. If the weight plane of two inputs is similar, then these inputs are highly correlated. This was used to assure that the features included are not highly correlated and to confirm previous analysis.

To identify DRFs with the highest prediction power, a feedforward backpropagation neural network was utilized. The good- and bad-response groups were divided into training and testing sets. For each feature, the daily DRFs for 50 patients (30 good- and 20 bad-responders with 28 fraction each, i.e., 840 (30 × 28) data points for good- and 560 (20 × 28) data points for bad-response group) were computed and used for the training. Combinations of either two or three of the DRFs that were previously selected using the t test and linear mixed-effect model, and were confirmed to be less correlated using the self-organizing map were used. Multiple models were examined using all possible two and three DRF combinations at a time. For each model, the neural network inputs (two or three daily DRFs) were nonlinearly mapped to three hidden neurons which were linearly mapped to an output variable.

However, two potential problems arise when optimizing a neural network, (1) a local minimum, where optimization terminate at a local not global minimum of the cost function, and (2) overfitting, where the model fits the noise in the training set. Generally, regularization by adding weight penalty terms to the cost function can help avoid these potential problems. However, it can be computationally intensive if the weights penalty is determined by validation. To efficiently determine the weight penalty parameters, a Bayesian regularization scheme (using “trainbr” function) was added to the neural network in the training process, leading to Bayesian neural network (BNN) model.35-40

By introducing Bayesian inference in the neural network, the optimal weight penalty parameter is estimated by a Bayesian approach to compute the likelihood of class membership given some characteristic of that class such that:

\[
p(w_j|t) = \frac{p(t|w_j)p(w_j)}{p(t)}
\]  

where, p (t|w_j) is the class conditioned probability or likelihood of target t given model parameter w, p (w_j) is a prior probability, p(t) is an evidence (usually ignored), and p(t|w) is the measurement conditioned or the posterior probability.

In a Multivariate Normal Bayesian Classification, given multiple classes, each class w_j has its own mean vector \( \mu_j \) and covariance matrix \( \Sigma_j \), such
that the class-conditional probabilities are
\[
p(t | w) = 2^n \cdot (2 - |C|) \cdot \exp \left( - \frac{1}{2} (t - m)^T \cdot C^{-1} \cdot (t - m) \right)
\]

To move from probabilities to discriminants we need to maximize \(\log(p(t | w))\) or \(\log(p(t | w_0) - \log(p(t | w)))\) and to link classical neural network with Bayesian statistics, minus the log likelihood is defined.\(^{42}\)

In other words, we need to maximize
\[
- \log(p(t | w)) = \frac{1}{2} \log|C| + \frac{1}{2} (t - m)^T \cdot C^{-1} \cdot (t - m)
\]

However, even with Bayesian regularization nonlinear neural network model, performance can be reduced when the model is evaluated over independent testing set. One possibility is that some values among the test can be considered outliers relative to the training data used in building the models. To overcome this potential problem, Mahalanobis distance can be used to consider the mean and the covariance matrix of each class, and hence, its spread in the multidimensional space.\(^{38}\)

In other word from Eq. 5, the expression \(- \frac{1}{2} (t - m)^T \cdot C^{-1} \cdot (t - m)\) can be thought of as \(\frac{1}{2} \left( |m - \bar{m}|^T \cdot C^{-1} \cdot |m - \bar{m}| \right)\), which looks like a squared distance multiplied by the inverse covariance matrix (c), that acts as a metric (stretching factor) on the space. Thus, using the Mahalanobis distance is equivalent to maximizing the likelihood \(p(t | w)\) used in Bayesian statistics.\(^{38}\)

Classification using BNN models incorporating the minimum (Mahalanobis) distance classifier (using “Mahal” function) can reduce the number of the data points classified as outliers. The results of the classification were the class with the highest probability (i.e., minimum distance to the centroid of the trained class as defined by the mean and covariance matrix of the model).

In our analysis for the training set, cross-validation (using “cvpartition” function) was performed using a leave-one-out method (one patient, with its all daily DRFs, is left out). Testing was performed using external independent validation sets of the daily DRFs from 40 patients not used for the training (20 good- and 20 bad-responders with 28 fractions each). A total of 120 weekly DRFs values from weeks 2–4 during the treatment were used to examine the performance of BNN. Classification was done using the minimum Mahalanobis distance to the centroid of the training class. The performance of each model was judged using the AUC. For each DRFs’s combination examined, to obtain the confidence intervals for the AUC, bootstraps sampling (using “bootstrap” function) was utilized with nboot = 100, i.e., from each bootstrap sample data one BNN model was trained, yielding 100 BNN models, and the ensemble mean of the resulting 100 BNN models was used as the final BNN model.

DATA AVAILABILITY

Data relating to the weekly DRFs for weeks 2–4 for the 50 good responders (150 data points) and the 40 bad responders (120 data points) for the best-performing feature combinations (kurtosis, entropy, and coarseness) that are used to generate the 3D plots, table showing the mean and standard deviation per fraction from all patients in the same response group for the relative net change of volume and sphericity for the good and bad response groups, figures showing the average changes over time for volume and sphericity showing overlap between the two response groups until the last week of treatment, which suggest that these features are not very useful for early prediction of treatment response, box plots of features showing significant differences between the two response groups (mean, SDN, entropy, and NESTD) combining all fractions and all patients in each response group, box plots of weekly change of a feature showing significant difference (kurtosis) and a feature not showing significant difference (IQR) for all patients and all fractions in the good and bad response groups, confusion matrix for the training and the external independent validation sets using the combination of kurtosis, coarseness, and NESTD features are available in the supplementary materials. Data are available from the corresponding author upon reasonable request.

CODE AVAILABILITY

Sample Matlab and R scripts are available in the supplementary materials. For our analysis, the pancreatic head was segmented in MIM 6.7.6 software (available at https://www.mimsoftware.com/). Radiomic features were extracted using IBEX software standalone version (available at https://www.dropbox.com/sh/tjk28tsb5tmots4/AADP9pkfpm2guDUY373MCR02a). MATLAB scripts were written with built-in MATLAB function in MATLAB R2015a version (available at https://www.mathworks.com/products/matlab.html). Codes are available from the corresponding author upon reasonable request.

REFERENCES

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics. CA Cancer J. Clin. 64, 9–29 (2014).
2. Landau, E. & Kalnicki, S. The evolving role of radiation in pancreatic cancer. Surg. Clin. North Am. 98, 113–125 (2018).
3. Krishnan, S. et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J. Radiat. Oncol. Biol. Phys. 15, 94, 755–765 (2016).
4. Griffin, J. F. et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 66, 56–61 (1990).
5. Brody, J. R. et al. Adenocarcinoma of the pancreas harbors KRAS2, DPC4 and TPS3 molecular alterations similar to pancreatic ductal adenocarcinoma. Mod. Pathol. 22, 651–659 (2009).
6. Cancer statistics. https://www.cancer.org/cancer/pancreatic-cancer/about/key-statistics.html, (2018).
7. Vignati, A. et al. Texture features on T2-weighted magnetic resonance imaging: new potential biomarkers for prostate cancer aggressiveness. Phys. Med Biol. 60, 2685–2701 (2015).
8. Zhen, G., Yan, S., Hng, Z., Wei, Z. & Hui, W. Radiogenomics helps to achieve personalized therapy by evaluating patient responses to radiation treatment. Cancerogene 36, 307–317 (2015).
9. Wibmer, A. et al. Haralick, texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. Eur. Radiol. 25, 2840–2853 (2015).
10. Teruel, J. R. et al. Dynamic contrast-enhanced MRI texture analysis for pretreatment prediction of clinical and pathological response to neoadjuvant chemotheraphy in patients with locally advanced breast cancer. NMRI Biomed. 27, 887–896 (2014).
11. Vallières, M., Freeman, C. R., Skamene, S. R. & El Naqa, I. A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities. Phys. Med. Biol. 60, 5471–5496 (2015).
12. Hou, Z. et al. Radiomic analysis in contrast-enhanced CT: predict treatment response to chemotheraphy in esophageal carcinoma. Oncotarget 8, 104444–104454 (2017).
13. Coroller, T. P. et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiother. Oncol. 114, 345–350 (2015).
14. Lambin, P. et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur. J. Cancer 48, 441–446 (2012).
15. Gillies, R. J., Kinahan, P. E. & Hricak H. Radiomics: images are more than pictures, they are data. Radiology 278, 563–577 (2015).
16. Larue, R. T., Defraene, G., De Ruyscher, D., Lambin, P. & van Elmp, W. Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. Br. J. Radio. 90, 20160665 (2017).
17. Virendra, K. et al. QIN radiomics: the process and the challenges. Magn. Reson. Imaging 30, 1234–1248 (2012).
18. Eilaghi, A. et al. CT texture features are associated with overall survival in pancreatic ductal adenocarcinoma – a quantitative analysis. Radiology Med. Imaging 17, 38 (2017).
19. Chen, X. et al. Assessment of treatment response during chemoradiation therapy for pancreatic cancer based on quantitative radiomic analysis of daily CTs: an exploratory study. PLOS ONE 12, e017896 (2017).
20. Garrido-Laguna, I. & Hidalgo, M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat. Rev. Clin. Onc. 12, 319–334 (2015).
21. Al-Kadi, O. & Waston, D. Texture analysis of aggressive and nonaggressive lung tumor CE CT images. IEEE Trans. Biomed. Eng. 55, 1822–1830 (2008).
22. Fave, X. et al. Using pretreatment radiomics and delta-radiomics features to predict nonsmall cell lung cancer patient outcomes. Int. J. Radiat. Oncol. Biol. Phys. 7, 588 (2017).
23. Ryan, R. et al. Pathological response following long-course neoadjuvant chemoradiation for locally advanced rectal cancer. Histopathology 47, 141–146 (2005).
24. Nasief, H. et al. Delta-radiomics of daily CTs acquired during chemoradiation therapy of pancreatic cancer. Med. Phys. 45, E140 (2018).
25. Zhang, L. et al. IBEX: an open infrastructure software platform to facilitate collaborative work in radiomics. Med. Phys. 42, 1341–1353 (2015).
26. Holub, O. & Ferreira, S. T. Quantitative histogram analysis of images. Comput. Phys. Commun. 175, 620–623 (2006).
27. Haralick, R. M., Shanmugam, K. & Dinstein, I. Textural features for image classification. IEEE Trans. Syst. Man Cybern. 3, 610–621 (1973).

Published in partnership with The Hormel Institute, University of Minnesota npj Precision Oncology (2019) 25

Received: 28 November 2018; Accepted: 9 September 2019; Published online: 04 October 2019
ACKNOWLEDGEMENTS

Discussions and inputs from Tia Plautz, PhD, George Noid, PhD, and Ying Zhang, PhD are greatly appreciated.

AUTHOR CONTRIBUTIONS

H.N. and X.A.L. conceived the idea and designed the study, H.N. compiled and analyzed the patient data, developed the machine-learning process, and drafted the paper. X.A.L. supervised the data analysis and edited and finalized the paper. D. Schott helped gather the data, analyzed the results, and reviewed the paper. C.Z. verified the statistical analyses, helped interpret the results, and reviewed the paper. B.E., W.H. and S.T. collected patient data, verified ROI contours, and edited the paper.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information is available for this paper at https://doi.org/10.1038/s41698-019-0096-z.

Correspondence and requests for materials should be addressed to X.A.L.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019